NERVGEN PHARMA CORP (NGEN.CA) Stock Price, Forecast & Analysis
Canada - TSX Venture Exchange - TSX-V:NGEN - CA64082X2032 - Common Stock
NGEN.CA Key Statistics, Chart & Performance
The current stock price of NGEN.CA is 5.8 CAD. In the past month the price increased by 77.54%. In the past year, price increased by 120.23%.
NGEN.CA Latest News, Press Relases and Analysis
NGEN.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TLRY.CA | TILRAY BRANDS INC | N/A | 11.42B | ||
| BHC.CA | BAUSCH HEALTH COS INC | 1.8 | 3.56B | ||
| CRON.CA | CRONOS GROUP INC | 23.07 | 1.32B | ||
| DHT-UN.CA | DRI HEALTHCARE TRUST | 7.32 | 907.11M | ||
| DHT-U.CA | DRI HEALTHCARE TRUST | 5.26 | 652.50M | ||
| WEED.CA | CANOPY GROWTH CORP | N/A | 589.54M | ||
| GUD.CA | KNIGHT THERAPEUTICS INC | N/A | 600.70M | ||
| CPH.CA | CIPHER PHARMACEUTICALS INC | 15.87 | 370.40M | ||
| ACB.CA | AURORA CANNABIS INC | N/A | 362.31M | ||
| HITI.CA | HIGH TIDE INC | N/A | 304.47M | ||
| OGI.CA | ORGANIGRAM GLOBAL INC | N/A | 304.93M | ||
| TSND.CA | TERRASCEND CORP | N/A | 273.61M |
Related stock screener links
About NGEN.CA
Company Profile
NervGen Pharma Corp. operates as a clinical stage biotech company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2019-03-13. The firm is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
Company Info
NERVGEN PHARMA CORP
112-970 Burrard Street, Unit 1290
Vancouver BRITISH COLUMBIA V7X 1J1 CA
CEO: Paul Brennan
Employees: 7
Phone: 17787311711
NERVGEN PHARMA CORP / NGEN.CA FAQ
What does NERVGEN PHARMA CORP do?
NervGen Pharma Corp. operates as a clinical stage biotech company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2019-03-13. The firm is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
What is the current price of NGEN stock?
The current stock price of NGEN.CA is 5.8 CAD. The price decreased by -5.84% in the last trading session.
Does NGEN stock pay dividends?
NGEN.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of NGEN stock?
NGEN.CA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
On which exchange is NGEN.CA stock listed?
NGEN.CA stock is listed on the TSX Venture Exchange exchange.
Can you provide the sector and industry classification for NERVGEN PHARMA CORP?
NERVGEN PHARMA CORP (NGEN.CA) operates in the Health Care sector and the Pharmaceuticals industry.
NGEN.CA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to NGEN.CA. When comparing the yearly performance of all stocks, NGEN.CA is one of the better performing stocks in the market, outperforming 89.87% of all stocks.
NGEN.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NGEN.CA. Both the profitability and financial health of NGEN.CA have multiple concerns.
NGEN.CA Financial Highlights
Over the last trailing twelve months NGEN.CA reported a non-GAAP Earnings per Share(EPS) of -0.39. The EPS decreased by -3.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -158.87% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NGEN.CA Forecast & Estimates
8 analysts have analysed NGEN.CA and the average price target is 7.24 CAD. This implies a price increase of 24.86% is expected in the next year compared to the current price of 5.8.